Skip to main content

Table 2 Therapeutic efficacy of artesunate + amodiaquine, artesunate + sulphadoxine-pyrimethamine, and amodiaquine + sulphadoxine-pyrimethamine among children with uncomplicated malaria in Faladje, Mali

From: Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali

Characteristics

AS+AQ (N= 131)

AS+SP (N = 130)

AQ+SP (N = 130)

PCR uncorrected responses on day 28: n (%)

   

Failures

58 (44.3)

12 (9.2)

3(2.3)

   ETF

0 (0)

2(1.5)

0(0)

   LCF

14 (10.7)

2(1.5)

1(0.8)

   LPF

44 (33.6)

8(6.2)

2(1.5)

*ACPR

73 (55.7)

118 (90.8)

127(97.7)

PCR corrected responses on day 28: n; %

   

Failures

6 (4.6)

4 (3.1)

1 (0.8)

   ETF

0 (0)

2(1.6)

0(0)

   LCF

2(1.5)

1(0.8)

0(0)

   LPF

4(3.1)

1(0.8)

1 (0.8)

**ACPR

124(95.4)

125(96.9)

129(99.2)

  1. AS+AQ, artesunate + amodiaquine; AS+SP, artesunate + sulphadoxine-pyrimethamine;
  2. AQ+SP, amodiaquine + sulphadoxine-pyrimethamine
  3. ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response.
  4. Failures are the combination of ETF, LCF, and LPF. Percentages are rounded to achieve 100% of totals.
  5. *X2 test: p < 0.001, AS+AQ vs. AS+SP; p < 0.001, AS+AQ vs. AQ+SP; p = 0.016, AS+SP vs. AQ+SP
  6. **X2 test: p = 0.17 for the comparison of the three treatment arms.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us